Biotechnology Research
Berkeley, CA
2-10 employees
Founded 2020
About CatenaBio
Catena Biosciences is a biotechnology company developing a proprietary protein conjugation platform to create novel therapeutics beyond the limits of current manufacturing. Its technology enables the creation of Multi-Payload Conjugates (MPCs)—a next-generation class of antibody-drug conjugates—offering enhanced stability and flexibility for targeted therapies. The company partners with pharmaceutical and biotechnology firms to accelerate the development of first- and best-in-class treatments.
Company Classification
Customer Types
B2B
Business Models
LicensingServices
Product & Service Types
Protein conjugation technology platformAntibody-Drug Conjugate (ADC) developmentTherapeutic development partnerships
Customers
| Customer | Success Story | Source |
|---|---|---|
| Partnered with CatenaBio to advance the development of new therapeutic modalities. Successfully produced 25 protein-protein conjugates from 10 starting proteins. Conjugated more than 1.5 g of product in less than 10 minutes. Modified cell surface for improved therapeutic performance. Conjugated to enable targeted gene delivery. |
Sign up to Ethos to access the full customer list, plus detailed competitor and product analysis.
Sign up to Ethos